The Economic Times - Jan 26, 2007

Ahmedabad: Marck Biosciences Ltd is in talks with several US-based pharma site-transfer deal whereby it can undertake contract manufacturing volume parenterals and injectibles at its facility in Gujarat. Through this process US-based pharma company can move iis production of a particular molecule to India by getting FDA approval for Marck's production facility Marck Bio managing director Bhavesh Patel told ET that getting FDA approval for specific product lines would take around six months. 'Pharma com; in the US and western Europe are looking at outsourcing  from India not only due to lower costs but also because of superior product Quality available here, “ says Patel. So far Marck’s export focus has been on the semi-regulated markets of CIS, Africa and Asia.

”We were constrained due to in sufficient capacities. But our Rs. 72 crore expansion getting completed by july this year. We can tap the global marketing in a big way," says Patel.